Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSA Heart Rhythm cohort of 12,812 patients found GLP-1 therapy reduced atrial fibrillation incidence (HR 0.67) and mortality (HR 0.34) versus matched controls. The protective effect persisted in patients who gained weight on therapy. Only semaglutide reached statistical significance, and the AF benefit took two years to appear.
Icotrokinra (Icotyde) is a macrocyclic 13-amino-acid peptide that blocks the IL-23 receptor at picomolar affinity. FDA approved March 18 for plaque psoriasis. Oral bioavailability comes from molecular engineering, not an absorption enhancer.
Vosoritide, the C-type natriuretic peptide analog approved for achondroplasia, lifts growth velocity by partially overriding FGFR3. A new review argues it also affects bone density, callus consolidation, and medullary canal anatomy in children going through limb lengthening.
A JAAD Case Reports paper attributes drug-induced hypersensitivity syndrome to a naturally-occurring GLP-1 mimetic. The finding lands as the FDA reviews broader access to peptides that supplement marketing frames as natural.
Bicycle Therapeutics' EphA2 BIA, a gallium-68-labeled bicyclic peptide, lit up liver, bone, lymph node, and peritoneal metastases across AACR 2026's first-in-human pancreatic cancer cohort.
A review in Naunyn-Schmiedeberg's maps the case for FOXO4-DRI, a retro-inverso peptide senolytic that selectively triggers apoptosis in senescent cells. In aged mouse models, it reversed hippocampal atrophy and cleared amyloid.
The biggest oncology meeting of the year has an accidental theme: peptides are powering at least three new drug classes landing at the same time. A map of who's there and what they showed.
A new analysis covering 54,680 transplant recipients found those on GLP-1 drugs were about half as likely to die. Heart problems dropped by about the same amount. The first clear picture for a high-risk population.
A late-stage substudy showed semaglutide lowering an Alzheimer's biological marker in spinal fluid. The same week, a peer-reviewed review mapped three peptide classes already in Alzheimer's trials.